Immunogenicity and duration of immunity in immunosuppressed children vaccinated with Human papillomavirus vaccine

Not Applicable

Completed

• Conditions: Human papillomavirus (HPV); Cancer - Cervical (cervix)

• Registration Number: ACTRN12608000260325
• Lead Sponsor: The Children's Hospital at Westmead

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-05-22
• Study Completion: 2016-02-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

Site One
Must be either a Bone Marrow, Renal or Liver transplant recipient with no medical contraindication or a child with inflammatory bowel disease who has been on long-term immunosuppressive medication Cannot have previously received immunisation with HPV Vaccine. Must have a platelet count of >50 Cannot have had immunoglobulin therapy within 3 months Cannot have a yeast allergy or any other known allergies to one of the vaccine component

Site Two
Must have a diagnosis of Rheumatic disease (such as Systemic Lupus Erythematosus or Juvenile Idiopathic Arthritis). Cannot have previously received immunisation with HPV Vaccine. Must have a platelet count of >50 Cannot have had immunoglobulin therapy within 3 months Cannot have a yeast allergy or any other known allergies to one of the vaccine component Cannot have had a flare of disease activity within three months prior to first dose of vaccine

Exclusion Criteria

- A platelet count of <50
- Immunoglobulin therapy within 3 months.
-Yeast allergy
- Any other known allergies to one of the vaccine component

Study & Design

• Study Type: Interventional
• Study Design: Not specified